Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
insitro expanded its ALS collaboration with Bristol Myers Squibb (NYSE: BMY) by adding two targets, ALS-2 and ALS-3, joining ALS-1 (nominated Dec 2024). insitro will advance an oligonucleotide for ALS-1 while BMY progresses a small molecule; insitro received a $10 million milestone.
Using its Virtual Human™ platform, insitro identified targets linked to TDP-43 mislocalization (~97% of ALS) and showed in iPSC-derived motor neurons rescue of neurite growth and reduction of cryptic exons.
Bristol Myers Squibb (NYSE: BMY) will present new clinical and real-world data for Camzyos (mavacamten) at ACC.26 (March 28–30, 2026). Key findings include positive Phase 3 SCOUT-HCM results in adolescents, multiple real-world studies confirming sustained effectiveness and safety, and up to five years of follow-up data.
Camzyos is approved in more than 60 countries, has been prescribed by over 4,500 HCPs to more than 22,000 U.S. patients, and remains available only through a REMS program because of LVEF/heart-failure risks.
Bristol Myers Squibb (NYSE: BMY) announced U.S. and EU approvals expanding Opdivo (nivolumab) indications for classical Hodgkin lymphoma (cHL) on March 20, 2026. In the U.S., Opdivo+AVD is approved for untreated Stage III/IV cHL in patients ≥12 years. In the EU, Opdivo+brentuximab vedotin is approved for relapsed/refractory cHL in patients 5–30 years after one prior therapy. The U.S. decision was supported by Phase 3 SWOG 1826 showing a 58% reduction in risk of progression or death (HR 0.42). Safety signals include 39% serious adverse reactions and 0.6% fatal reactions in SWOG 1826.
Bristol Myers Squibb (NYSE: BMY) will report first-quarter 2026 results on April 30, 2026. Company executives will discuss results on a conference call beginning at 8:00 a.m. ET and a live audio webcast will be available at investor.bms.com.
Materials will be posted on the Investor Relations site before the call, and a replay will be available approximately three hours after the call concludes.
Contact emails: media@bms.com and investor.relations@bms.com.
Bristol Myers Squibb (NYSE: BMY) announced positive interim Phase 3 results from the SUCCESSOR-2 study of oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) in relapsed or refractory multiple myeloma. MeziKd showed a statistically significant, clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone.
Safety was consistent with the known profile; patients will continue to be followed for overall survival and long-term safety. Data will be presented at a future medical meeting and shared with health authorities.
Bristol Myers Squibb (NYSE:BMY) announced FDA approval of Sotyktu (deucravacitinib) for adults with active psoriatic arthritis on March 7, 2026. Approval was supported by pivotal POETYK PsA-1 and PsA-2 trials where Sotyktu 6 mg once daily achieved ACR20 rates of 54% vs placebo 34% (PsA-1) and 54% vs placebo 39% (PsA-2) at Week 16. Common adverse reactions include upper respiratory infections, increased CPK, herpes simplex, mouth ulcers, folliculitis, and acne. Warnings include infections, malignancy including lymphomas, rhabdomyolysis, laboratory abnormalities, and potential risks related to JAK inhibition.
Bristol Myers Squibb (NYSE: BMY) declared a quarterly cash dividend of $0.63 per share. The Board set the dividend payable on May 1, 2026 to shareholders of record as of April 2, 2026.
This action returns cash to shareholders and reflects a scheduled quarterly distribution policy.
SystImmune and Bristol Myers Squibb (NYSE: BMY) reported that izalontamab brengitecan (iza-bren) met both dual primary endpoints of progression-free survival (PFS) and overall survival (OS) in a pre-specified interim analysis of a Phase III study (BL-B01D1-307; NCT06382142) in previously treated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in China.
This is the third Phase III trial where iza-bren reached primary endpoint(s) and the first bispecific ADC in Phase III to report dual positive PFS/OS results in TNBC; data will be presented at an upcoming medical meeting.
Bristol Myers Squibb (NYSE: BMY) will participate in the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. The company will appear in a fireside chat beginning at 9:50 a.m. ET.
Investors and the public can listen via the company investor site at http://investor.bms.com, and an archived recording will be available after the session.
Bristol Myers Squibb (NYSE: BMY) reported positive top-line results from an ex‑US Phase 2 registrational study (NCT05664737) of Reblozyl (luspatercept) in adults with alpha (α)-thalassemia.
Both non‑transfusion‑dependent and transfusion‑dependent cohorts met primary and key secondary endpoints: an Hb increase in NTD and ≥50% RBC transfusion reduction in TD. Safety matched Reblozyl's known profile. Data will be presented at a medical congress and discussed with China's regulator.